The long-term study of a new medicine (galegenimab) in people with a type of eye disease (geographic atrophy secondary to age-related macular degeneration)
A Study Assessing the Long-Term Safety and Tolerability of RG6147 in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration
Eye Disorder Macular Degeneration Age-Related Macular Degeneration Dry Macular Degeneration Geographic Atrophy
For the latest version of this information please go to www.forpatients.roche.com